本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ascendis Pharma A/S

223.81
-3.1900-1.41%
成交量:22.55万
成交额:5,079.03万
市值:148.14亿
市盈率:17.62
高:228.91
开:225.99
低:223.67
收:227.00
52周最高:282.15
52周最低:186.05
股本:6,618.99万
流通股本:6,553.95万
量比:0.53
换手率:0.34%
股息:- -
股息率:- -
每股收益(TTM):12.70
每股收益(LYR):-4.4176
净资产收益率:118.78%
总资产收益率:9.58%
市净率:9.21
市盈率(LYR):-50.66

数据加载中...

2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/07

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/02

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]